Enrollment ongoing in Phase 2 KOURAGE trial of AuxoraTM in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025 ...

Enrollment ongoing in Phase 2 KOURAGE trial of Auxora in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025 Post-hoc analysis of ...

Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Data From Cohorts 1-3 anticipated to be Presented in MayInitial Results From First Two ...

Good morning, ladies and gentlemen, and welcome to the Humacyte fourth quarter results conference call. (Operator Instructions) As a reminder, this conference call is being recorded. I'll now turn the ...

Pre-specified interim analysis of Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI) is expected to ...

Pulse Biosciences, Inc. (NASDAQ: PLSE) Q4 2024 Earnings Call Transcript March 27, 2025 Pulse Biosciences, Inc. beats earnings ...

To register for BPK 896 or BPK 897, complete and submit the enrollment forms availble on the Forms and Resources page. Optional specialization in translational and integrative neuroscience (TRAIN) ...

Philip Taylor; Investor Relations; Pulse Biosciences Inc. Paul Laviolette; Co-Chairman of the Board, President, Chief Executive Officer; Pulse Biosciences Inc. Jon S ...

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for high unmet need ...

Pre-specified interim analysis of Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI) is expected to be completed in Q2 2025Company expects to complete analy ...

BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the fiscal year ended December 31, 2024, ...